Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2017!
Start-up meeting associated with initiation of clinical studies of Ergoferon
Four extensive multicenter randomized trials have been completed which evaluated the safety and efficacy of two release-active drugs – liquid Ergoferon and Rengalin – in children and adults with acute respiratory infections (ARIs).
Laboratory of Influenza under Pasteur Institute and APcis carried out a study in cooperation with Materia Medica Holding.
Opening Research Laboratory - breakthrough in comprehensive studies and manufacturing developments
Pharmaceutical company OOO "NPF "Materia Medica Holding" has obtained GMP certificates from Slovakia and Ukraine
Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2016!
Officials of Mexico National Institute of Pediatrics confirmed recommendations on Anaferon for children application for prevention and treatment of acute infectious respiratory diseases
Materia Medica expands manufacturing unit
3rd Drug Discovery & Therapy World Congress
First Russian GMP certificate
7 International Congress of Antibodies
Antiviral drug ANAFERON became the laureate of Premium “Brand of the Year No. 1 in Russia” in Kremlin!
Anaferon for children has been recognized by European Respiratory Society as an effective drug for the treatment of recurring viral upper respiratory infections in children with bronchial asthma
23rd Congress on Clinical Microbiology and Infectious Diseases (Berlin)
The trial of Anaferon for children in Vietnam
Impaza medicine is registered in Mexico
ISO 9001-2011 (ISO 9001:2008) Quality Management Systems - Audited and Certified
Impaza has been authorized in Mexico